Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

Healthcare Expenses Increase After GLP-1 Prescription

L.A. McKeown

August 18, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Daily News

Time-Restricted Eating Tightens Glycemic Control in Patients With Metabolic Syndrome

Caitlin E. Cox

October 04, 2024

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Daily News

Regaining Weight Won’t Erode CV Risk Factor Benefits Short Term

L.A. McKeown

March 31, 2023

News Daily News

‘Redlining’ of Neighborhoods Left a Legacy of Poorer CV Health

L.A. McKeown

July 04, 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

Shelley Wood

May 27, 2021

News Conference News ACC 2021

Social Determinants of Health Tied to Fewer COVID-19 Precautions in CVD Patients

Caitlin E. Cox

May 07, 2021

News Features

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Michael O'Riordan

April 24, 2020

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Todd Neale

March 28, 2020

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

Todd Neale

November 17, 2019

News Daily News

Disparate US Trends in Early CVD Deaths Speak to Need for Targeted Prevention

Caitlin E. Cox

October 21, 2019

News Industry News

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

October 02, 2017

Advertisement

Healthcare Expenses Increase After GLP-1 Prescription

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

January 2025 Dispatch for the CV Team

Time-Restricted Eating Tightens Glycemic Control in Patients With Metabolic Syndrome

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Regaining Weight Won’t Erode CV Risk Factor Benefits Short Term

‘Redlining’ of Neighborhoods Left a Legacy of Poorer CV Health

Dapagliflozin Boosts Health Status Across LVEF Range

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

Social Determinants of Health Tied to Fewer COVID-19 Precautions in CVD Patients

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Dapagliflozin Has Benefits Across Heart Failure Subgroups

Disparate US Trends in Early CVD Deaths Speak to Need for Targeted Prevention

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content